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Abstract 
Objective: To report our initial experience with Drug Coated Balloon (DCB) only angioplasty 
and propose a protocol to achieve this safely. 
Background: There are no articles published in the literature currently regarding the safety of 
same day discharge in patients treated with DCB-only angioplasty. 
Methods: Retrospective review of all our patients treated with DCB-only angioplasty from Sept 
2017 to April 2018 with identification of potential complications relating to same day 
discharge.   
Results: A total of 100 consecutive patients who underwent elective DCB-only angioplasty for 
de novo coronary artery disease and were discharged on the same day as the procedure were 
included. In 99% no cardiac symptoms relating to the procedure requiring urgent 
hospitalisation or urgent investigations were identified. One patient was readmitted the next 
day requiring stenting of the previously treated lesion. Our 30 day mortality was zero. Some 
97 hospital bed days were saved with 100 patients treated. 
Conclusion: Elective day-case DCB-only angioplasty according to our local protocol is safe 
and cost-effective and should be considered for the majority of the patients. 
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Introduction 
Drug coated balloon (DCB) only angioplasty in de novo coronary lesions, is an alternative to 
routine elective drug eluting stent implantation (DES) (1) (2) (3) . In our institution this 
constitutes 44% of all elective, urgent and emergency PCI. Given the constant pressures on 
hospital beds, there is an increasing demand for fast and efficient, yet safe turn-around of all 
elective patients, ideally as day cases. Although there is ample evidence for same day discharge 
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in patients receiving an intra coronary stent, no prior study has reported on this strategy in 
DCB-only de novo angioplasty (4) (5). An important safety consideration, particularly with 
DCB only angioplasty, is acute vessel closure due to a higher risk of coronary dissection, which 
will usually be apparent peri-procedurally and will necessitate emergency treatment (6) (7). 
The default position to defer discharge to the following day is therefore readily understandable 
particularly where an intracoronary stent has not been deployed to scaffold the vessel.   In this 
article we report our experience with same day discharge following DCB-only angioplasty 
from a high-volume UK centre and propose a protocol to achieve this safely.  
 
Methods 
We identified all patients who underwent elective DCB angioplasty at the Norfolk and Norwich 
University Hospital between September 2017 and April 2018 and were discharged on the day 
of their procedure. A local protocol had been proposed for guidance (Figure I) but ultimately 
the decision for same day discharge was left to the Consultant Interventional Cardiologist in 
charge of the patient’s care. In our institution elective patients can be considered for same day 
discharge following balloon angioplasty if they fulfil the following criteria: 
1) They are pain-free 
2) There are no new changes on the post-PCI ECG  
3) There is no more than type B coronary artery dissection as defined by Rahman et al. (8), and  
4) Absence of high-risk procedural features (such as coronary perforation, occlusion of 
significant side branch, vascular complications) 
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Figure I: Flow diagram for elective drug coated balloon angioplasty patients 
 
All patients were routinely contacted via telephone post-discharge to identify any 
complications relating potentially to the procedure. Institutional approval was received for use 
of data for the purposes of this manuscript. Survival data was obtained from the Office of 
National Statistics, a national registry where all deaths are reported.  
 
Results 
One hundred consecutive patients with a total of 113 de novo lesions and 10 in-stent re-stenosis 
lesions were included (eight patients had in-stent restenosis only whilst two had both in-stent 
restenosis and de novo disease, giving a total of 105 de novo only lesions in 92 patients). The 
baseline characteristics demonstrate the unselected nature of the patients; 30% had diabetes 
mellitus, 41% had a previous myocardial infarction, 56% had undergone previous PCI, 9% had 
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* High-risk procedural features such as coronary artery perforation, occlusion of 
significant side branch, vascular complications 
Same day discharge post Drug Coated Balloon Angioplasty 
1) Relative at home 
2) Phone at home 
Overnight stay 
1) Pain free 
2) No new ECG changes post-DCB 
3) No more than type B dissection 
4) No high risk procedural features* 
Overnight stay 
Discharge with advice after 4-6 
hours of observation 
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undergone coronary artery bypass grafting surgery (CABG), 55% had hypertension and 69% 
were current or ex-smokers, as shown in table I. Women were under-represented comprising 
only 19% of the cohort. However, this is in keeping with the general relative proportion of 
women undergoing PCI in the UK over the last few years, which is 25%(9).  
 
Table I: Demographics of patients undergoing elective day – case Drug Coated Balloon 
Angioplasty 
Number of patients 100 
Mean Age (years) +/- SD 67 ±10.3  
Females 19  
Diabetes 30  
Previous Myocardial Infarction 41  
Previous PCI 56  
Hypertension 55  
CABG 9  
Smoking history (current/previous) 69 
PCI: Percutaneous Coronary Intervention, CABG: Coronary Artery Bypass Graft. SD: 
Standard Deviation 
Table I: Demographics of patients undergoing elective day – case Drug Coated Balloon 
Angioplasty 
 
The greater majority of procedures (97%) were completed via the transradial route. The drug 
coated balloons used were SeQuent Please NEO, 2-4mm in diameter and 10-40mm in length. 
A total of 140 drug coated balloons were used, 91 with diameter >2.8mm and 49 with diameter 
<2.8mm, as shown in tables II and III. Two experienced operators (SCE/IM) reviewed all the 
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angiograms and graded the severity of the treated lesions according to the ACC/AHA 
classification system (A-C).(10) A total of 52.0% were type C coronary lesions, 36.6% were 
type B and only 11.4% were type A lesions. All procedures were also reviewed for any visible 
dissections which were graded according to the National Heart, Lung and Blood Institute 
(NHLBI) classification.(8) Out of 123 treated lesions, 62 (50.4%) had no angiographic 
evidence of dissection, 18 (14.6%) had type A dissection, 42 (34.1%) had type B dissection 
and 1 (0.8%) had type D dissection, which had not been appreciated during the procedure or 
the time of discharge, as shown in table IV. 
Table II: Angiographic details of patients undergoing elective day-case Drug Coated Balloon 
Angioplasty 
Number of lesions 123 
Lesion type  
     A 14 (11.4%) 
     B1 23 (18.7%) 
     B2 22 (17.9%) 
     C 64 (52.0%) 
Bifurcations 28 
Heavy calcification 26 
Chronic total occlusions 7 
Thrombus 1 
Small vessel (<2.8mm) 
Non-small vessel (>2.8mm) 
49 
91  
Vessel treated / out of 123 lesions  
    LMS 2 (1.6%) 
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Table II: Angiographic details of patients undergoing elective day-case Drug Coated Balloon 
Angioplasty 
 
    LAD 57 (46.3%) 
    Diagonal 7 (5.7%) 
    LCx 22 (17.9%) 
    Marginal 10 (8.1%) 
    Intermediate 3 (2.4%) 
    RCA 21 (17%) 
    Vein graft 1 (0.8%) 
DCB: Drug Coated Balloon, LMS: Left Main Stem, LAD: Left Anterior Descending, LCx: 
Left Circumflex, RCA: Right Coronary Artery. 
Table III: Procedural characteristics of patients undergoing elective day-case Drug Coated 
Balloon Angioplasty 
Access 
  Radial 
  Femoral 
 
97 
3 
Number of DCBs used 140 
DCB diameter 
Mean 
Range 
 
2.99mm 
Min = 2, Max = 4mm 
DCB Length range 10-40mm 
Average DCB Length 23.25mm 
Average Fluoroscopy time 14.6minutes 
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Table III: Procedural characteristics of patients undergoing elective day-case Drug Coated 
Balloon Angioplasty 
 
 
Table IV: Core lab analysis elective day-case Drug Coated Balloon Angioplasty 
Dissection type 
No angiographic dissection 62 (50.4%) 
A 18 (14.6%) 
B 42 (34.1%) 
D 1 (0.8%) 
Table IV: Core lab analysis elective day-case Drug Coated Balloon Angioplasty 
 
According to the Office of National Statistics, a national body where all deaths are recorded by 
law, our 30-day mortality was zero. The overall complication rate was 1%.  There were no 
vascular complications and no cases of contrast nephropathy reported. In cases at risk of 
contrast nephropathy, we routinely undertake all necessary steps to minimise the risk with 
adequate intravenous pre-hydration and limited use of contrast. Our average contrast volume 
of 130mls justifies this reassuring result. During our follow-up telephone contact, nighty-nine 
patients did not report any cardiac related symptoms requiring urgent hospitalisation or urgent 
investigations. One patient was admitted the day after the procedure with cardiac chest pain, 
ECG changes and serial troponin rise of 150, 160 and 148 ng/L (normal <14). Urgent 
angiography revealed TIMI II flow in the target vessel requiring stent implantation. The patient 
Average Contrast Volume (SD) 129.6 ±48.6ml 
Radiation skin dose 1091 mGy 
DCB: Drug Coated Balloon, SD: Standard Deviation 
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made an uneventful recovery and was discharged home the next day. Retrospective review of 
the index procedure demonstrated a type D dissection that had not been previously appreciated 
due to suboptimal imaging.  
 
Discussion 
Acute vessel closure due to coronary artery dissection is one of the most significant 
complications of balloon angioplasty. Early studies have shown that type A and B coronary 
artery dissections if left untreated have good long term outcomes.(11) This is the first study to 
report on same day discharge in consecutive patients undergoing DCB-only angioplasty and 
propose safe criteria to achieve this (figure 1). The case mix of the patients included supports 
that this can be achieved across all patients with multiple comorbidities and complex lesions. 
DCB is an emerging interventional strategy in the extensive armamentarium of Interventional 
Cardiologists both in the elective and emergency setting. (12) The existing pressures on 
hospital beds nationally exacerbated by the winter crises places greater emphasis on more 
efficient utilisation of inpatients beds for our elective patients without compromising unduly 
on patient safety. Our study confirms that day-case DCB angioplasty is safe, with zero 30-day 
mortality, and carries a low complication rate in an unselected patient population and can 
improve cost-effectiveness. After one hundred consecutive patients, ninety-seven days in 
hospital were saved. With an excess bed day of £306 according to 2015-16 reference costs 
published from the Department of Health, UK, we estimate that day-case DCB angioplasty can 
save about £296 per procedure in the UK. (13) Recent data from the United States demonstrate 
that same-day discharge after PCI is associated with larger cost savings of $5128 per procedure, 
(7) while transradial same-day discharge PCI in Canada was associated with savings of Can$ 
1,141 mainly due to the extra night for overnight hospital stay. (8) Obviously, the economic 
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benefits of day-case DCB angioplasty will be of greater relevance in countries with more 
expensive overnight hospital stays.  
The retrospective nature of our work from a single-centre is a limitation as it can introduce 
referral bias. However, we are a large tertiary referral centre providing cardiac intervention to 
a population in excess of one million and we included consecutive patients to ensure 
recruitment bias is minimised. The strength of our study is that it represents real world data and 
that we included and followed up all (consecutive and unselected) patients who met the 
inclusion criteria during our study duration. Therefore, we believe that our conclusions can 
easily be generalised to patients undergoing elective DCB-only angioplasty in other 
institutions.  
 
Conclusion 
Our study has shown that where DCB can be used for the treatment of de novo coronary artery 
disease, same day discharge of all elective patients according to our protocol can be considered 
and is cost-effective. 
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